Growth & Performance
CJC 1295 + IPAMORELIN 5mg
5MG · blend
Order & shipping details
Quantity breaks: 5 = −10% · 10 = −15%. Bulk pricing at qty ≥ 10.
- Typically ships the same business day — orders before 3:00 PM PST
- Discreet packaging — nothing on the outside
- Arrived damaged? Contact support — we'll help
View certificate of analysis →
On the record
This Lot's Certificate of Analysis
The certificate below is the one issued for the lot printed on the vial. Read it in full, or look it up at the lab that ran it.
CJC 1295 + IPAMORELIN 5mg
Lot VR108082500001-10 · HPLC purity >99.5% · Vanguard Laboratory · report V260618-8 006 · reported 1 Jul 2026
What this is
A research blend pairing CJC-1295 (a growth-hormone-releasing-hormone analog) with ipamorelin (a selective growth-hormone secretagogue), in one vial. 5mg of each.
The two compounds do genuinely different jobs, and that is the entire logic of the pairing:
- CJC-1295 is a GHRH analog. It acts at the growth-hormone-releasing-hormone receptor — the same receptor the hypothalamic hormone uses.
- Ipamorelin is a selective pentapeptide growth-hormone secretagogue acting on the ghrelin (GHS-R) receptor. Different receptor, different pathway, same downstream system.
Two different receptors feeding one axis is why this specific combination shows up so often in growth-hormone research. It is not a stronger version of one compound; it is two distinct inputs.
Note that this blend uses CJC-1295 without DAC. If you want the Drug Affinity Complex version, that is a separate product: CJC-1295 W/DAC, which is bound to a complex that extends its activity in circulation. The two are not interchangeable.
Research profile
Pairing a GHRH analog with a ghrelin-receptor secretagogue is one of the most-studied combinations in growth-hormone-axis research.
CJC-1295 is used in the literature as a model for GHRH-receptor signalling — the upstream, hypothalamic input into the axis.
Ipamorelin is studied in growth-hormone-axis research as a model for selective GH release with minimal effect on other hormones. The word "selective" is the interesting one: much of the published interest in ipamorelin comes from how narrow its receptor activity is compared with earlier secretagogues, which makes it a cleaner probe.
Research suggests the two-receptor approach is studied precisely because it lets researchers separate the contributions of the two pathways. That is a methodological reason for the pairing, not a claim about combined magnitude.
Neither compound is an approved drug, and nothing on this page is guidance for use.
Specifications
| Property | This lot |
|---|---|
| Compounds | CJC-1295 (no DAC) · Ipamorelin |
| Labelled mass | 5mg + 5mg |
| Reported chromatographic purity | >99.50 Area%, HPLC-UV/VIS |
| Certificate status | Published — Vanguard Laboratory, ID V260618-8 006 |
| Physical form | Lyophilized blend |
| Storage (unopened) | −20°C |
| Reconstitution | Bacteriostatic water — one reconstitution puts both into solution |
| Lot | VR108082500001-10 |
| CAS | Not applicable — blends carry no single registry number |
Lab testing and this lot's certificate
Every lot goes to Vanguard Laboratory, an independent A2LA-accredited lab (A2LA certificate #6377.01.01) in Olympia, Washington — HPLC-UV/VIS purity, assay quantity, LAL endotoxin.
For lot VR108082500001-10, the certificate is published and downloadable from this page. Laboratory ID V260618-8 006, reported 1 July 2026: chromatographic purity >99.50 Area% by HPLC-UV/VIS, and endotoxins passing by LAL at <5.00 EU/mg.
On a blend, the quantity line is the one to read. HPLC resolves the two compounds separately, so the certificate reports CJC-1295 5.55mg and Ipamorelin 5.41mg as distinct results rather than one combined mass — which is what tells you the split is real and roughly even.
Reported by Dustin Newman, Laboratory Director; approved by Tori Johnson, Operations Manager. Results relate only to lot VR108082500001-10.
Handling and storage
Lyophilized blend. One reconstitution puts both peptides into solution together.
Sealed at −20°C. One diluent addition puts both compounds into solution at a fixed 1:1 mass ratio. If you need to vary the ratio, buy ipamorelin separately.
The reconstitution reference on this page converts diluent volume into concentration. It is a reference for in-vitro laboratory handling only. Its outputs describe the physical properties of the reconstituted vial — concentration and mass drawn — and are not dosing guidance, administration instructions, or medical advice.
Bacteriostatic water sold separately.
Questions
Does this contain CJC-1295 with DAC?
No. This blend uses CJC-1295 without the Drug Affinity Complex. The DAC version is a separate product with a longer circulating profile.
Why combine two compounds that both affect growth hormone?
They act at two different receptors — GHRH receptor and ghrelin (GHS-R) receptor. Researchers pair them to study two distinct inputs into one axis, not to double a single input.
What does "selective" mean for ipamorelin?
That its receptor activity is comparatively narrow relative to earlier secretagogues, which makes it a cleaner experimental probe.
Is the certificate published?
Yes. Lot VR108082500001-10 has a published certificate — open the PDF straight from this page. Every published certificate is also on the lab tests page.
Can I buy the two separately?
Ipamorelin, yes — 10mg vial. CJC-1295 is currently only stocked in the DAC form as a standalone, and in this blend without DAC.
Research Use Only. This product is sold for in-vitro research use only. It is not a drug, not a supplement, and not for human or veterinary use. Hello Stacks makes no claims regarding the safety, efficacy or suitability of any compound for any use, and publishes no dosing guidance.